Marc Weiner

6.3k total citations · 1 hit paper
77 papers, 4.0k citations indexed

About

Marc Weiner is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Marc Weiner has authored 77 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Infectious Diseases, 36 papers in Epidemiology and 15 papers in Pharmacology. Recurrent topics in Marc Weiner's work include Tuberculosis Research and Epidemiology (40 papers), Antifungal resistance and susceptibility (16 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Marc Weiner is often cited by papers focused on Tuberculosis Research and Epidemiology (40 papers), Antifungal resistance and susceptibility (16 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Marc Weiner collaborates with scholars based in United States, Uganda and South Africa. Marc Weiner's co-authors include Stephen E. Weis, Andrew Vernon, Charles A. Peloquin, William J. Burman, Margarita E. Villarino, Lorna Bozeman, Erin Bliven-Sizemore, Debra Benator, William J. Yount and Richard E. Chaisson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Marc Weiner

73 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

2011 630 citations Timothy R. Sterling, Margarita E. Villarino et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Weiner United States	35	3.3k	2.5k	1.1k	414	354	77	4.0k
Andrew Vernon United States	34	3.8k 1.2×	3.0k 1.2×	1.8k 1.6×	437 1.1×	385 1.1×	58	4.7k
Richard Hafner United States	40	3.4k 1.0×	3.7k 1.5×	722 0.6×	491 1.2×	215 0.6×	86	5.2k
Wing Wai Yew China	38	3.1k 0.9×	2.6k 1.0×	1.2k 1.0×	679 1.6×	215 0.6×	111	4.5k
Kelly E. Dooley United States	36	3.5k 1.1×	2.4k 1.0×	1.3k 1.2×	577 1.4×	418 1.2×	141	4.6k
Rodney Dawson South Africa	38	3.3k 1.0×	2.5k 1.0×	1.1k 1.0×	808 2.0×	410 1.2×	82	4.4k
Jotam G. Pasipanodya United States	35	2.7k 0.8×	2.0k 0.8×	565 0.5×	424 1.0×	957 2.7×	86	3.5k
Max Salfinger United States	38	4.3k 1.3×	4.1k 1.6×	1.8k 1.6×	723 1.7×	358 1.0×	113	5.7k
Susan E. Dorman United States	44	3.9k 1.2×	3.6k 1.4×	1.5k 1.3×	559 1.4×	178 0.5×	130	5.6k
Srikanth Tripathy India	36	2.6k 0.8×	1.5k 0.6×	600 0.5×	440 1.1×	104 0.3×	236	4.2k
Antonio Rivero Spain	40	2.6k 0.8×	3.3k 1.3×	385 0.3×	270 0.7×	147 0.4×	307	6.3k

Countries citing papers authored by Marc Weiner

Since Specialization

Citations

This map shows the geographic impact of Marc Weiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Weiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Weiner more than expected).

Fields of papers citing papers by Marc Weiner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Weiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Weiner. The network helps show where Marc Weiner may publish in the future.

Co-authorship network of co-authors of Marc Weiner

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Weiner. A scholar is included among the top collaborators of Marc Weiner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Weiner. Marc Weiner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiner, Marc, et al.. (2021). Acute kidney injury with partial Fanconi syndrome in a patient with leptospirosis: a case report. Journal of Medical Case Reports. 15(1). 358–358. 2 indexed citations

Weiner, Marc, et al.. (2021). Correction to: Acute kidney injury with partial Fanconi syndrome in a patient with leptospirosis: a case report. Journal of Medical Case Reports. 15(1). 434–434.

Savić, Radojka M., Martin J. Boeree, Charles A. Peloquin, et al.. (2021). Optimising pyrazinamide for the treatment of tuberculosis. European Respiratory Journal. 58(1). 2002013–2002013. 23 indexed citations

Wendler, Jason, Aaron Wright, Paul Piehowski, et al.. (2021). Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region. PLoS ONE. 16(5). e0250586–e0250586. 6 indexed citations

Dorman, Susan E., Amina Jindani, Kelly E. Dooley, et al.. (2020). Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine. 202(6). 866–877. 22 indexed citations

Weiner, Marc, Jon Gelfond, Teresa L. Johnson‐Pais, et al.. (2020). Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. Journal of Antimicrobial Chemotherapy. 76(3). 582–586. 13 indexed citations

Wendler, Jason, Erin Baker, Kristin Burnum-Johnson, et al.. (2018). Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis. Tuberculosis. 112. 52–61. 15 indexed citations

Belknap, Robert, David P. Holland, Pei-Jean Feng, et al.. (2017). Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection. Annals of Internal Medicine. 167(10). 689–697. 103 indexed citations

Luetkemeyer, Anne F., Cynthia Firnhaber, Michelle A. Kendall, et al.. (2016). Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clinical Infectious Diseases. 62(9). 1081–1088. 58 indexed citations

10.

Andrews, Charles P. & Marc Weiner. (2015). Immunodiagnosis of Invasive Pulmonary Aspergillosis in Rabbits. American Review of Respiratory Disease.

11.

Dorman, Susan E., Radojka M. Savić, Stefan Goldberg, et al.. (2014). Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial. American Journal of Respiratory and Critical Care Medicine. 191(3). 333–343. 76 indexed citations

12.

Nahid, Payam, Erin Bliven-Sizemore, Leah G. Jarlsberg, et al.. (2014). Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis. 94(3). 187–196. 50 indexed citations

13.

Weiner, Marc, Eric F. Egelund, Melissa Engle, et al.. (2013). Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. Journal of Antimicrobial Chemotherapy. 69(4). 1079–1085. 42 indexed citations

14.

Groote, Mary Ann De, Payam Nahid, Leah G. Jarlsberg, et al.. (2013). Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. PLoS ONE. 8(4). e61002–e61002. 89 indexed citations

15.

Dooley, Kelly E., Erin Bliven-Sizemore, Marc Weiner, et al.. (2012). Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 91(5). 881–888. 61 indexed citations

16.

Nahid, Payam, Jussi Saukkonen, William R. Mac Kenzie, et al.. (2011). Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. American Journal of Respiratory and Critical Care Medicine. 184(8). 972–979. 41 indexed citations

17.

Weiner, Marc, Debra Benator, W. J. Burman, et al.. (2005). Association between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and Tuberculosis. Clinical Infectious Diseases. 40(10). 1481–1491. 170 indexed citations

18.

Weiner, Marc, Naomi Bock, Charles A. Peloquin, et al.. (2004). Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during Once-Weekly Tuberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 169(11). 1191–1197. 62 indexed citations

19.

Weiner, Marc, William J. Burman, Andrew Vernon, et al.. (2003). Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. American Journal of Respiratory and Critical Care Medicine. 167(10). 1341–1347. 151 indexed citations

20.

Moreno, Francisco, James H. Jorgensen, & Marc Weiner. (1994). An old antibiotic for a new multiple-resistant Enterococcus faecium?. Diagnostic Microbiology and Infectious Disease. 20(1). 41–43. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact